GE HealthCare Technologies (NASDAQ:GEHC) Rating Lowered to “Hold” at Zacks Research

GE HealthCare Technologies (NASDAQ:GEHC) was downgraded by research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a note issued to investors on Monday,Zacks.com reports.

A number of other equities research analysts have also recently issued reports on GEHC. Wall Street Zen cut shares of GE HealthCare Technologies from a “buy” rating to a “hold” rating in a research report on Saturday, September 20th. Citigroup increased their target price on shares of GE HealthCare Technologies from $89.00 to $93.00 and gave the stock a “buy” rating in a research report on Thursday, July 31st. Morgan Stanley set a $74.00 price objective on shares of GE HealthCare Technologies in a report on Thursday, September 18th. Finally, BTIG Research reissued a “buy” rating on shares of GE HealthCare Technologies in a report on Monday, July 14th. Seven research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $86.89.

GE HealthCare Technologies Trading Up 2.8%

Shares of GEHC stock opened at $75.10 on Monday. GE HealthCare Technologies has a 52-week low of $57.65 and a 52-week high of $94.80. The stock has a market cap of $34.29 billion, a price-to-earnings ratio of 15.39, a P/E/G ratio of 2.79 and a beta of 1.13. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.93 and a current ratio of 1.16. The firm has a fifty day moving average of $74.30 and a 200-day moving average of $72.67.

GE HealthCare Technologies (NASDAQ:GEHC) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.91 by $0.15. The company had revenue of $5 billion during the quarter, compared to analysts’ expectations of $4.96 billion. GE HealthCare Technologies had a net margin of 11.22% and a return on equity of 23.93%. The business’s revenue was up 3.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.00 EPS. GE HealthCare Technologies has set its FY 2025 guidance at 4.430-4.630 EPS. On average, equities research analysts forecast that GE HealthCare Technologies will post 4.68 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Corient Private Wealth LLC boosted its stake in GE HealthCare Technologies by 1.4% during the 2nd quarter. Corient Private Wealth LLC now owns 56,872 shares of the company’s stock worth $4,212,000 after acquiring an additional 767 shares during the last quarter. Caldwell Trust Co acquired a new stake in GE HealthCare Technologies during the 2nd quarter worth approximately $1,532,000. Valeo Financial Advisors LLC raised its holdings in GE HealthCare Technologies by 43.5% during the 2nd quarter. Valeo Financial Advisors LLC now owns 10,900 shares of the company’s stock worth $807,000 after buying an additional 3,303 shares during the period. Osaic Holdings Inc. raised its holdings in GE HealthCare Technologies by 18.1% during the 2nd quarter. Osaic Holdings Inc. now owns 224,869 shares of the company’s stock worth $16,674,000 after buying an additional 34,499 shares during the period. Finally, Orion Porfolio Solutions LLC raised its holdings in GE HealthCare Technologies by 13.0% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 78,061 shares of the company’s stock worth $5,782,000 after buying an additional 8,959 shares during the period. Institutional investors own 82.06% of the company’s stock.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.